FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385285> ?p ?o ?g. }

• W4308385285 abstract "<h3>Background</h3> Immunotherapy +/- chemotherapy is currently the standard of care for metastatic NSCLC, but strategies to expand the benefit are still needed. Oligometastatic NSCLC is a state of limited disease in which widespread metastasis has not yet evolved. Locally radiotherapy achieves prolonged progression- free survival and overall survival in a small proportion of well selected oligometastatic NSCLC patients¹. Preliminary evidence suggests high dose fractionated radiotherapy, such as SBRT, in combination with systemic immunotherapy has a synergistic effect and may enhance survival². Durvalumab (PD-L1 antibody) is approved as consolidation therapy for unresectable, locally advanced NSCLC who have not progressed following chemoradiotherapy. These findings support further investigation of durvalumab + SBRT combinations in oligometastatic NSCLC who received standard systematic therapy. <h3>Methods</h3> SABRCURE is an open-label, phase 2 study evaluating the efficacy and safety of durvalumab combined with SBRT and chemotherapy in oligometastatic stage IV NSCLC. Key eligibility criteria include no more than 5 metastatic lesions in up to 3 organs, EGFR/ALK/ROS1 wild type, no previous systemic therapy or brain metastases. Forty patients will be enrolled and receive durvalumab 1500mg + platinum-doublet chemotherapy every 3 weeks for 4 cycles, and then durvalumab 1500mg every 4 weeks monotherapy until disease progression or up to 24 months. Patient without progression after 4 cycles durvalumab + chemotherapy will receive stereotactic body radiotherapy. SBRT will be started within 2 weeks after chemotherapy completion and administered to primary lesion and all known metastatic lesions, with a total dose of 50-60Gy in≤10 fractions. The primary endpoint is progression free survival (PFS) per RECIST v1.1. Secondary end points are objective response rate (ORR), overall survival (OS) , safety and treatment failure pattern. This study was funded by AstraZeneca China. <h3>Trial Registration</h3> NCT04255836 <h3>References</h3> Gomez DR, Tang C, Zhang J, <i>et al</i>. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. <i>J. Clin. Oncol.</i> 2019;<b>37</b>(18):1558. Azghadi S, Daly ME. Radiation and immunotherapy combinations in non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i>. 2021;<b>26</b>:100298. <h3>Ethics Approval</h3> This study was approved by Cancer Hospital of the University of Chinese Academy of Sciences Ethics Committee. <h3>Consent</h3> Written informed consent was obtained from the patient for publication of this abstract." @default.
• W4308385285 created "2022-11-11" @default.
• W4308385285 creator A5005461513 @default.
• W4308385285 creator A5044512741 @default.
• W4308385285 creator A5047645246 @default.
• W4308385285 creator A5065482772 @default.
• W4308385285 creator A5066879163 @default.
• W4308385285 creator A5084585443 @default.
• W4308385285 date "2022-11-01" @default.
• W4308385285 modified "2023-09-25" @default.
• W4308385285 title "698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)" @default.
• W4308385285 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0698" @default.
• W4308385285 hasPublicationYear "2022" @default.
• W4308385285 type Work @default.
• W4308385285 citedByCount "0" @default.
• W4308385285 crossrefType "proceedings-article" @default.
• W4308385285 hasAuthorship W4308385285A5005461513 @default.
• W4308385285 hasAuthorship W4308385285A5044512741 @default.
• W4308385285 hasAuthorship W4308385285A5047645246 @default.
• W4308385285 hasAuthorship W4308385285A5065482772 @default.
• W4308385285 hasAuthorship W4308385285A5066879163 @default.
• W4308385285 hasAuthorship W4308385285A5084585443 @default.
• W4308385285 hasBestOaLocation W43083852851 @default.
• W4308385285 hasConcept C121608353 @default.
• W4308385285 hasConcept C126322002 @default.
• W4308385285 hasConcept C126838900 @default.
• W4308385285 hasConcept C143998085 @default.
• W4308385285 hasConcept C2776256026 @default.
• W4308385285 hasConcept C2776694085 @default.
• W4308385285 hasConcept C2777701055 @default.
• W4308385285 hasConcept C2777742743 @default.
• W4308385285 hasConcept C2780030458 @default.
• W4308385285 hasConcept C509974204 @default.
• W4308385285 hasConcept C71924100 @default.
• W4308385285 hasConceptScore W4308385285C121608353 @default.
• W4308385285 hasConceptScore W4308385285C126322002 @default.
• W4308385285 hasConceptScore W4308385285C126838900 @default.
• W4308385285 hasConceptScore W4308385285C143998085 @default.
• W4308385285 hasConceptScore W4308385285C2776256026 @default.
• W4308385285 hasConceptScore W4308385285C2776694085 @default.
• W4308385285 hasConceptScore W4308385285C2777701055 @default.
• W4308385285 hasConceptScore W4308385285C2777742743 @default.
• W4308385285 hasConceptScore W4308385285C2780030458 @default.
• W4308385285 hasConceptScore W4308385285C509974204 @default.
• W4308385285 hasConceptScore W4308385285C71924100 @default.
• W4308385285 hasLocation W43083852851 @default.
• W4308385285 hasOpenAccess W4308385285 @default.
• W4308385285 hasPrimaryLocation W43083852851 @default.
• W4308385285 hasRelatedWork W2357406576 @default.
• W4308385285 hasRelatedWork W2407189953 @default.
• W4308385285 hasRelatedWork W2413020017 @default.
• W4308385285 hasRelatedWork W2418514417 @default.
• W4308385285 hasRelatedWork W2922707684 @default.
• W4308385285 hasRelatedWork W3115829157 @default.
• W4308385285 hasRelatedWork W3137670083 @default.
• W4308385285 hasRelatedWork W3175383630 @default.
• W4308385285 hasRelatedWork W4319794037 @default.
• W4308385285 hasRelatedWork W1899415052 @default.
• W4308385285 isParatext "false" @default.
• W4308385285 isRetracted "false" @default.
• W4308385285 workType "article" @default.